Biogen Advances Alzheimer's Drug to Phase 3 Despite Mixed Mid-Stage Data

Biogen has announced its decision to advance an experimental Alzheimer's disease treatment, Diranersen, into late-stage Phase 3 clinical trials. This move comes despite disappointing results from mid-stage testing, where the drug failed to demonstrate superior responses at higher doses. The biopharmaceutical company justified this progression by citing compelling signals that the treatment effectively decreases levels of tau, a protein linked to memory loss, and slows cognitive decline, particularly at the lowest administered dose. Dr. Priya Singhal, Biogen's head of development, emphasized that the combination of tau reduction in pathology and cognitive benefits meets the necessary criteria for Phase 3 advancement. This development marks another step in Biogen's complex history with Alzheimer's research, following the controversial withdrawal of Aduhelm and the market launch of Leqembi. Unlike previous amyloid-targeting drugs, Diranersen is an antisense oligonucleotide designed to limit tau production. The announcement highlights Biogen's continued commitment to overcoming challenges in neurodegenerative disease treatment, even as rival Eli Lilly pursues similar tau-targeting therapies. The decision reflects a strategic bet on specific biological markers over broad dose-response efficacy in earlier trials.